Humana Inc. (NYSE:HUM) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 1.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,707 shares of the insurance provider’s stock after selling 481 shares during the period. Handelsbanken Fonder AB’s holdings in Humana were worth $19,094,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in HUM. Rakuten Securities Inc. acquired a new position in Humana during the fourth quarter worth approximately $25,000. Gradient Investments LLC lifted its stake in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after buying an additional 40 shares during the last quarter. Nvwm LLC lifted its stake in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after buying an additional 25 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in Humana in the fourth quarter valued at approximately $55,000. Finally, Operose Advisors LLC purchased a new stake in Humana in the third quarter valued at approximately $56,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 0.9 %

Humana stock opened at $325.30 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The firm has a market capitalization of $39.25 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. Humana Inc. has a fifty-two week low of $299.23 and a fifty-two week high of $541.21. The stock’s fifty day moving average is $330.09 and its two-hundred day moving average is $399.70.

Humana (NYSE:HUM) last posted its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The firm had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period last year, the company posted $1.62 EPS. Analysts predict that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.09%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio (DPR) is 17.86%.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Jefferies Financial Group reduced their price objective on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research note on Monday. TheStreet cut Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Truist Financial reiterated a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Argus cut Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Finally, Deutsche Bank Aktiengesellschaft cut Humana from a “buy” rating to a “hold” rating and cut their price target for the stock from $595.00 to $360.00 in a research note on Thursday, January 25th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $454.63.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.